NASDAQ:TNON Tenon Medical Q2 2023 Earnings Report $1.16 +0.01 (+0.87%) As of 04:00 PM Eastern Earnings HistoryForecast Tenon Medical EPS ResultsActual EPS-$0.33Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ATenon Medical Revenue ResultsActual Revenue$0.74 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATenon Medical Announcement DetailsQuarterQ2 2023Date8/8/2023TimeN/AConference Call DateTuesday, August 8, 2023Conference Call Time4:30PM ETUpcoming EarningsTenon Medical's Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportConference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Tenon Medical Q2 2023 Earnings Call TranscriptProvided by QuartrAugust 8, 2023 ShareLink copied to clipboard.There are 4 speakers on the call. Operator00:00:00Greetings, and welcome to the Tenen Medical Second Quarter 2023 Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded. Your hosts today are Steve Foster, Chief Executive Officer and President and Steve Van Dyck, Chief Financial Officer. Mr. Foster and Mr. Operator00:00:22Van Dyck will present results of operations for the Q2 ended June 30, 2023, and provide a corporate update. A press release detailing these results was released today is available on the Investor Relations section of our company's website, www.tenonmed.com. Before we begin the formal presentation, I would like to remind everyone that statements made on the call and webcast may include predictions, estimates and other information that may be considered forward looking. While these forward looking statements represent our current judgment on what the future holds, They are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward Looking Statements, which reflect our opinions only as of the date of this presentation. Operator00:01:18Please keep in mind that we are not obliging ourselves to revise or publicly release the results of any revision to these forward looking statements in light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our predictions. For a more complete discussion of these factors and other risks, you should review our prospectus dated April 26, 2022, particularly under the heading Risk Factors, which is on file with the Securities and Exchange Commission at www.sec.gov. At this time, I'll turn the call over to Tennant Medical's Chief Executive Officer, Steve Foster. Please go ahead, sir. Speaker 100:02:11Thank you, Madeleine, and good afternoon, everyone. I'm pleased to welcome you to today's Q2 2023 financial results corporate update conference call for Tennon Medical. Over the course of our record Q2, we achieved $743,000 in revenue, representing a triple digit growth of 4 50% year over year and 72% sequentially from the Q1. Our fully commercialized catamaran system Designed to deliver a refined surgical option for patients with chronic sacroiliac joint pain or degenerative sacroiliac The fatal conservative care is rapidly gaining momentum and increasing surgical procedures. We marked an important milestone in the 2nd quarter With gross profit and gross margin turning positive at $194,000 26%, respectively. Speaker 100:03:09Our positive second quarter reflects a focus on building our commercial infrastructure and sales management team. We continue to target physicians who have been trained on SI procedures or have significant experience with SI Surgical Technologies by facilitating an aggressive local workshop training program. We are showcasing our unique solution through a wide variety of channels, Conferences and hands on workshops, which include a combination of our local synthetic model and cataveric lab workshops All of these critical activities are designed to drive acceleration in the number of procedures completed with the catamaran system. Confirming our approach during the Q2, our surgical procedures increased 4 69% compared to the year ago quarter. To reach our sales goals, we continue to execute our go to market strategy during the Q2, hosting 43 physicians in catamaran workshops. Speaker 100:04:18These sessions are designed to highlight the effectiveness and ease of use of our product as well as how the inferior posterior approach to the optimized pathway into the anatomy. This distinct implant system addresses a significant unmet market opportunity and is designed to produce broad and demonstrable advantages over market competitors. Building on the momentum of the Q2, we expect the number of surgical procedures to In Q3, representing our continued commitment to ongoing innovation, Tanan will initiate a limited release of our newly refined system to deliver catamaran starting in September 2023. These enhanced tools promise to deliver upgraded and Imaging. With that, I'll turn it over to Mr. Speaker 100:05:33Van Dyck, our Chief Financial Officer, to discuss our financials. Speaker 200:05:40Thank you, Steve. I'll give us a sneak review of our financial results. A Full breakdown is available in our press release that crossed the wire this afternoon. Our 2nd quarter revenue was $743,000 an increase of 4.53 50 percent compared to $135,000 in the comparable year ago period. Revenue for the 1st 6 months of this year was $1,200,000 an increase of 4.71% compared to $206,000 in the same period last year. Speaker 200:06:15The increase in revenue for the 3 6 months of this year as compared to the same periods in 2022 was primarily due to increases of 4 69% and 4 76%, respectively, in the number of surgical procedures in which the catamaran system was used. Gross profit in the Q2 of this year was $194,000 or 26 percent of revenue, compared to a gross loss of $136,000 or a negative 101% of revenue in the comparable year ago period. For the 1st 6 months of this year, gross profit was $147,000 or 13% of revenue compared to a gross loss of $340,000 or a negative 165 percent of revenue for the 1st 6 months of 2022. Gross margin percent improved due to higher revenue associated with the increase in the number of surgical procedures. Operating losses totaled $4,300,000 for our Q2 compared to a loss of $5,500,000 in the Q2 of 2022. Speaker 200:07:30The decrease in operating expenses were a result of the arbitration settlement and other consulting expenses in Q2 of 2022, offset by an increase in stock based compensation, increases in sales and marketing and general expenses. For the 1st 6 months of this year, operating losses totaled $9,200,000 compared to $7,500,000 in the prior year period. The increase in operating expenses were a result of an increase in stock based compensation, increases in sales and marketing and general expenses as the company builds its sales function and infrastructure to support future growth. The net loss was $4,300,000 in our Q2 compared to a loss of $5,500,000 in the same period of 2022. For the 1st 6 months of this year, net loss was $9,100,000 compared to $7,800,000 in the previous year period. Speaker 200:08:32The company expects to incur additional losses in the future. As of June 30, 2023, cash and cash I'll now turn the call back to Steve for his closing thoughts. Speaker 100:08:55Thank you, Steve. With the accelerating pace of catamaran procedures, we're very optimistic for continued growth in the commercialization of our proprietary FDA Cleared Surgical Implant System. We marked the 2nd quarter with strong revenue gains and a positive gross margin and believe we can continue on this growth trajectory with our expanding commercial infrastructure and seasoned sales management team. Looking ahead, the revenue growth combined with our recent capital raise positions us appropriately to further accelerate our momentum in the second half of the year. We continue to reinforce our commitment to validating and differentiating patient outcomes and radiographic assessment with ongoing post market clinical studies and expect to expand the application of our distinct product offering to address SI revision surgery, We look forward to additional updates in the months to come as we continue to expand our sales infrastructure and execute on our growth objectives to deliver long term value to our shareholders. Speaker 100:10:06I thank everyone for attending. And I would like to hand the call over to the operator to begin our question and answer session. Operator00:10:21With Covering You will be placed into the queue in the order received. Please be prepared to ask your question when prompted. Our first question comes from Bruce Jackson with The Benchmark Company. Bruce, you may now ask your question. Speaker 300:10:53Hi, good afternoon and thank you for taking my questions. First off, congrats on achieving gross profit Positivity, the number of doctors trained in the quarter is 43, it's up sequentially. Is that something that You can do can you continue to increase the number of doctors who are trained next quarter? Speaker 100:11:18Yes. Hi, Bruce. This is Steve. Thank you for the congrats and the question. I do believe we can continue to Expand that number. Speaker 100:11:26As our sales team gets comfortable, trained, up to speed, etcetera, and frankly, as they broaden their activities, All of this feeds on itself and I do anticipate that number to continue to expand and grow. Speaker 300:11:42Okay. And then are you still happy with the synthetic training model? Is that helping you out at all? Speaker 100:11:49Very much so. Look, the physicians are extraordinarily busy. The degree to which we can bring A workshop session to them, make it very convenient, do it in an evening or over a weekend or what have you, really pays dividends That keeps them from having to jump on a plane and go someplace, etcetera. So we are leveraging this Synthetic model to do local programs, to bring faculty in virtually to talk through with the physicians about Their experience with the technology and what have you and it seems to be extremely well received and quite honestly Bruce it lets us move more quickly. Getting a trip planned for position takes time with their tough schedules, bringing it to them lets us move very quickly When they're ready to be exposed to the system. Speaker 300:12:46Okay. That's great. Then in terms of the physicians that you Have trained in, who have performed procedure. How well Are they repeating the procedures? Is it something where they've been trained and then they get comfortable with it and then they start Performing the procedures in a routine fashion? Speaker 100:13:10Indeed, sure. In these early stage Of course, we're looking to see if our technology is sticky, that if people get trained and So used to the technology, do they adopt and do they stick with it and keep rolling and we're really happy With what we see on that front, the technology is proving to be reproducible over and over again. And that goes to this inferior posterior approach that we've talked a little bit about Bruce on several occasions. This I want to really stress, this is a unique way of getting at this anatomy, different from any other competitor that we have. We believe that approach will prove to be a more efficient, reproducible Pathway that stays away from neuro and vascular structures and gives a physician the comfort that they can get where they need to be and get the job done. Speaker 100:14:09And of course, we're early. We launched this technology just a couple of quarters ago. So we're early in the process, but what we're seeing is that is coming to fruition. And it makes us really encouraged as we expose physicians to the technology. We watch their reaction And we watch how quickly they come back and reproducibly use the technology to serve their patients. Speaker 100:14:35So Really encouraged in what we're seeing. Speaker 300:14:38Okay. Then last topic is the new delivery system. So maybe you could like Tell us a little bit about how much it differs from the current delivery system and are the doctors who are trained on the current Speaker 100:15:02We do believe that well, let me back up. 1st and foremost, Medical Device is about constant iteration And improvements, you hear from your physician customers, if you're smart enough to listen carefully, you can really improve the way The technology feels in their hands, the sequence of instrumentation, things of that nature, and we're exceptionally focused on that as a small organization. We want to respond very quickly to those kinds of feedback. And that's what we've done here. I talked about Graft handling, this is just when we drill the 2 holes, we harvest that the patient's own bone and pack our implant with that graft. Speaker 100:15:48Handling that graph can be a bit tedious, etcetera. We believe we've come up with some great ideas to make that process faster, more Frankly, more gratifying for the staff and the physician alike. The access profile, this is the access sleeve through which we Put the implant, is shrinking pretty dramatically approximately 40%. And of course, every physician wants to do as little Soft tissue disruption as humanly possible, but yet still get the job done effectively. And so that's what that's all about. Speaker 100:16:23And we believe through this alpha that we call it this sort of test period, We have proved out that we're reducing the size of that access requirement in the incision size pretty dramatically. And then 3rd, you always want the entire procedure to be satisfying for the physician. You want things to be stable, Intuitive, easy for the nurses to support, things of that nature. And so we've taken a number of steps to continue That refinement process. You asked about access, that's exactly right. Speaker 100:17:01We've been quite aggressive With how we put this alpha together, it will be somewhat limited in September, just to make sure everything we've done is delivering on its promises And that our physician advisors are satisfied and then we're in a position to make the technology available rather aggressively to our physician users and it just involves a small add on tray to our existing base tray In the procedure, so it's relatively straightforward for them to have access to the technology. Speaker 300:17:35Okay, great. Actually, I have one more question. Financial question, is the income statement profile in the Q3 going to look Like the Q1 or the Q2 of this year, you had a little bit of a downtick in the SG and A line. So is that going to come back up with the increased Activity or is that like the level this quarter, is that the level that you would expect going forward? Speaker 200:18:02Yes, Bruce, thanks for that. I think you're going to find it somewhere in between. I think the SG and A, of course, is going to go up with higher revenues The commission structure, but the R and D and general Administrative, the G and A costs should remain relatively flat Q2 to Q3, Except we may see some increase in the stock compensation, the Stock based compensation line. Speaker 300:18:37Okay, great. That's all I've got. Thank you very much. Speaker 100:18:43Thank you, Operator00:18:48Bruce. At this time, it appears there are no further questions. I would now like to turn the call back over to Mr. Foster for his closing remarks. Speaker 100:19:08Thank you, Madeleine. So I'd like to thank each of you for joining our earnings conference call today and look forward to continuing to update you on our ongoing progress and growth. If we were unable to answer any of your questions, please reach out to our IR firm, MZ Group, We'll be more than happy to assist. With that, I wish everyone a good day.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallTenon Medical Q2 202300:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Tenon Medical Earnings HeadlinesAlliance Global Partners Initiates Coverage of Tenon Medical (TNON) with Buy RecommendationApril 10, 2025 | msn.comTenon Medical initiated with a Buy at Alliance Global PartnersApril 9, 2025 | markets.businessinsider.comM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big change. Make America Wealthy Again (M.A.W.A).April 30, 2025 | Paradigm Press (Ad)Tenon Medical files to sell 5.67M shares of common stock for holdersApril 5, 2025 | markets.businessinsider.comTenon gets FDA clearance for Catamaran SI Joint Fusion System indicationMarch 26, 2025 | markets.businessinsider.comTenon Medical prices $2.5M registered direct offering at $2.00March 26, 2025 | markets.businessinsider.comSee More Tenon Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tenon Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenon Medical and other key companies, straight to your email. Email Address About Tenon MedicalTenon Medical (NASDAQ:TNON), a medical device company, engages in the development of surgical implant systems to treat severe lower back pain in the United States and Puerto Rico. The company offers CATAMARAN SI-Joint Fusion System to fuse sacroiliac joints (SI-Joints) to treat SI-Joint dysfunction that often causes severe lower back pain; and features fixation device that passes through the axial and sagittal planes of the ilium and sacrum, as well as transfixes the SI joints. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.View Tenon Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon's Earnings Will Make or Break the Stock's Comeback CrowdStrike Stock Nears Record High, Dip Ahead of Earnings?Alphabet Rebounds After Strong Earnings and Buyback AnnouncementMarkets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryMarket Anticipation Builds: Joby Stock Climbs Ahead of Earnings Upcoming Earnings Airbnb (5/1/2025)Apple (5/1/2025)Amazon.com (5/1/2025)Amgen (5/1/2025)Linde (5/1/2025)MercadoLibre (5/1/2025)Monster Beverage (5/1/2025)Strategy (5/1/2025)Atlassian (5/1/2025)Arthur J. Gallagher & Co. (5/1/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 4 speakers on the call. Operator00:00:00Greetings, and welcome to the Tenen Medical Second Quarter 2023 Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded. Your hosts today are Steve Foster, Chief Executive Officer and President and Steve Van Dyck, Chief Financial Officer. Mr. Foster and Mr. Operator00:00:22Van Dyck will present results of operations for the Q2 ended June 30, 2023, and provide a corporate update. A press release detailing these results was released today is available on the Investor Relations section of our company's website, www.tenonmed.com. Before we begin the formal presentation, I would like to remind everyone that statements made on the call and webcast may include predictions, estimates and other information that may be considered forward looking. While these forward looking statements represent our current judgment on what the future holds, They are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward Looking Statements, which reflect our opinions only as of the date of this presentation. Operator00:01:18Please keep in mind that we are not obliging ourselves to revise or publicly release the results of any revision to these forward looking statements in light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our predictions. For a more complete discussion of these factors and other risks, you should review our prospectus dated April 26, 2022, particularly under the heading Risk Factors, which is on file with the Securities and Exchange Commission at www.sec.gov. At this time, I'll turn the call over to Tennant Medical's Chief Executive Officer, Steve Foster. Please go ahead, sir. Speaker 100:02:11Thank you, Madeleine, and good afternoon, everyone. I'm pleased to welcome you to today's Q2 2023 financial results corporate update conference call for Tennon Medical. Over the course of our record Q2, we achieved $743,000 in revenue, representing a triple digit growth of 4 50% year over year and 72% sequentially from the Q1. Our fully commercialized catamaran system Designed to deliver a refined surgical option for patients with chronic sacroiliac joint pain or degenerative sacroiliac The fatal conservative care is rapidly gaining momentum and increasing surgical procedures. We marked an important milestone in the 2nd quarter With gross profit and gross margin turning positive at $194,000 26%, respectively. Speaker 100:03:09Our positive second quarter reflects a focus on building our commercial infrastructure and sales management team. We continue to target physicians who have been trained on SI procedures or have significant experience with SI Surgical Technologies by facilitating an aggressive local workshop training program. We are showcasing our unique solution through a wide variety of channels, Conferences and hands on workshops, which include a combination of our local synthetic model and cataveric lab workshops All of these critical activities are designed to drive acceleration in the number of procedures completed with the catamaran system. Confirming our approach during the Q2, our surgical procedures increased 4 69% compared to the year ago quarter. To reach our sales goals, we continue to execute our go to market strategy during the Q2, hosting 43 physicians in catamaran workshops. Speaker 100:04:18These sessions are designed to highlight the effectiveness and ease of use of our product as well as how the inferior posterior approach to the optimized pathway into the anatomy. This distinct implant system addresses a significant unmet market opportunity and is designed to produce broad and demonstrable advantages over market competitors. Building on the momentum of the Q2, we expect the number of surgical procedures to In Q3, representing our continued commitment to ongoing innovation, Tanan will initiate a limited release of our newly refined system to deliver catamaran starting in September 2023. These enhanced tools promise to deliver upgraded and Imaging. With that, I'll turn it over to Mr. Speaker 100:05:33Van Dyck, our Chief Financial Officer, to discuss our financials. Speaker 200:05:40Thank you, Steve. I'll give us a sneak review of our financial results. A Full breakdown is available in our press release that crossed the wire this afternoon. Our 2nd quarter revenue was $743,000 an increase of 4.53 50 percent compared to $135,000 in the comparable year ago period. Revenue for the 1st 6 months of this year was $1,200,000 an increase of 4.71% compared to $206,000 in the same period last year. Speaker 200:06:15The increase in revenue for the 3 6 months of this year as compared to the same periods in 2022 was primarily due to increases of 4 69% and 4 76%, respectively, in the number of surgical procedures in which the catamaran system was used. Gross profit in the Q2 of this year was $194,000 or 26 percent of revenue, compared to a gross loss of $136,000 or a negative 101% of revenue in the comparable year ago period. For the 1st 6 months of this year, gross profit was $147,000 or 13% of revenue compared to a gross loss of $340,000 or a negative 165 percent of revenue for the 1st 6 months of 2022. Gross margin percent improved due to higher revenue associated with the increase in the number of surgical procedures. Operating losses totaled $4,300,000 for our Q2 compared to a loss of $5,500,000 in the Q2 of 2022. Speaker 200:07:30The decrease in operating expenses were a result of the arbitration settlement and other consulting expenses in Q2 of 2022, offset by an increase in stock based compensation, increases in sales and marketing and general expenses. For the 1st 6 months of this year, operating losses totaled $9,200,000 compared to $7,500,000 in the prior year period. The increase in operating expenses were a result of an increase in stock based compensation, increases in sales and marketing and general expenses as the company builds its sales function and infrastructure to support future growth. The net loss was $4,300,000 in our Q2 compared to a loss of $5,500,000 in the same period of 2022. For the 1st 6 months of this year, net loss was $9,100,000 compared to $7,800,000 in the previous year period. Speaker 200:08:32The company expects to incur additional losses in the future. As of June 30, 2023, cash and cash I'll now turn the call back to Steve for his closing thoughts. Speaker 100:08:55Thank you, Steve. With the accelerating pace of catamaran procedures, we're very optimistic for continued growth in the commercialization of our proprietary FDA Cleared Surgical Implant System. We marked the 2nd quarter with strong revenue gains and a positive gross margin and believe we can continue on this growth trajectory with our expanding commercial infrastructure and seasoned sales management team. Looking ahead, the revenue growth combined with our recent capital raise positions us appropriately to further accelerate our momentum in the second half of the year. We continue to reinforce our commitment to validating and differentiating patient outcomes and radiographic assessment with ongoing post market clinical studies and expect to expand the application of our distinct product offering to address SI revision surgery, We look forward to additional updates in the months to come as we continue to expand our sales infrastructure and execute on our growth objectives to deliver long term value to our shareholders. Speaker 100:10:06I thank everyone for attending. And I would like to hand the call over to the operator to begin our question and answer session. Operator00:10:21With Covering You will be placed into the queue in the order received. Please be prepared to ask your question when prompted. Our first question comes from Bruce Jackson with The Benchmark Company. Bruce, you may now ask your question. Speaker 300:10:53Hi, good afternoon and thank you for taking my questions. First off, congrats on achieving gross profit Positivity, the number of doctors trained in the quarter is 43, it's up sequentially. Is that something that You can do can you continue to increase the number of doctors who are trained next quarter? Speaker 100:11:18Yes. Hi, Bruce. This is Steve. Thank you for the congrats and the question. I do believe we can continue to Expand that number. Speaker 100:11:26As our sales team gets comfortable, trained, up to speed, etcetera, and frankly, as they broaden their activities, All of this feeds on itself and I do anticipate that number to continue to expand and grow. Speaker 300:11:42Okay. And then are you still happy with the synthetic training model? Is that helping you out at all? Speaker 100:11:49Very much so. Look, the physicians are extraordinarily busy. The degree to which we can bring A workshop session to them, make it very convenient, do it in an evening or over a weekend or what have you, really pays dividends That keeps them from having to jump on a plane and go someplace, etcetera. So we are leveraging this Synthetic model to do local programs, to bring faculty in virtually to talk through with the physicians about Their experience with the technology and what have you and it seems to be extremely well received and quite honestly Bruce it lets us move more quickly. Getting a trip planned for position takes time with their tough schedules, bringing it to them lets us move very quickly When they're ready to be exposed to the system. Speaker 300:12:46Okay. That's great. Then in terms of the physicians that you Have trained in, who have performed procedure. How well Are they repeating the procedures? Is it something where they've been trained and then they get comfortable with it and then they start Performing the procedures in a routine fashion? Speaker 100:13:10Indeed, sure. In these early stage Of course, we're looking to see if our technology is sticky, that if people get trained and So used to the technology, do they adopt and do they stick with it and keep rolling and we're really happy With what we see on that front, the technology is proving to be reproducible over and over again. And that goes to this inferior posterior approach that we've talked a little bit about Bruce on several occasions. This I want to really stress, this is a unique way of getting at this anatomy, different from any other competitor that we have. We believe that approach will prove to be a more efficient, reproducible Pathway that stays away from neuro and vascular structures and gives a physician the comfort that they can get where they need to be and get the job done. Speaker 100:14:09And of course, we're early. We launched this technology just a couple of quarters ago. So we're early in the process, but what we're seeing is that is coming to fruition. And it makes us really encouraged as we expose physicians to the technology. We watch their reaction And we watch how quickly they come back and reproducibly use the technology to serve their patients. Speaker 100:14:35So Really encouraged in what we're seeing. Speaker 300:14:38Okay. Then last topic is the new delivery system. So maybe you could like Tell us a little bit about how much it differs from the current delivery system and are the doctors who are trained on the current Speaker 100:15:02We do believe that well, let me back up. 1st and foremost, Medical Device is about constant iteration And improvements, you hear from your physician customers, if you're smart enough to listen carefully, you can really improve the way The technology feels in their hands, the sequence of instrumentation, things of that nature, and we're exceptionally focused on that as a small organization. We want to respond very quickly to those kinds of feedback. And that's what we've done here. I talked about Graft handling, this is just when we drill the 2 holes, we harvest that the patient's own bone and pack our implant with that graft. Speaker 100:15:48Handling that graph can be a bit tedious, etcetera. We believe we've come up with some great ideas to make that process faster, more Frankly, more gratifying for the staff and the physician alike. The access profile, this is the access sleeve through which we Put the implant, is shrinking pretty dramatically approximately 40%. And of course, every physician wants to do as little Soft tissue disruption as humanly possible, but yet still get the job done effectively. And so that's what that's all about. Speaker 100:16:23And we believe through this alpha that we call it this sort of test period, We have proved out that we're reducing the size of that access requirement in the incision size pretty dramatically. And then 3rd, you always want the entire procedure to be satisfying for the physician. You want things to be stable, Intuitive, easy for the nurses to support, things of that nature. And so we've taken a number of steps to continue That refinement process. You asked about access, that's exactly right. Speaker 100:17:01We've been quite aggressive With how we put this alpha together, it will be somewhat limited in September, just to make sure everything we've done is delivering on its promises And that our physician advisors are satisfied and then we're in a position to make the technology available rather aggressively to our physician users and it just involves a small add on tray to our existing base tray In the procedure, so it's relatively straightforward for them to have access to the technology. Speaker 300:17:35Okay, great. Actually, I have one more question. Financial question, is the income statement profile in the Q3 going to look Like the Q1 or the Q2 of this year, you had a little bit of a downtick in the SG and A line. So is that going to come back up with the increased Activity or is that like the level this quarter, is that the level that you would expect going forward? Speaker 200:18:02Yes, Bruce, thanks for that. I think you're going to find it somewhere in between. I think the SG and A, of course, is going to go up with higher revenues The commission structure, but the R and D and general Administrative, the G and A costs should remain relatively flat Q2 to Q3, Except we may see some increase in the stock compensation, the Stock based compensation line. Speaker 300:18:37Okay, great. That's all I've got. Thank you very much. Speaker 100:18:43Thank you, Operator00:18:48Bruce. At this time, it appears there are no further questions. I would now like to turn the call back over to Mr. Foster for his closing remarks. Speaker 100:19:08Thank you, Madeleine. So I'd like to thank each of you for joining our earnings conference call today and look forward to continuing to update you on our ongoing progress and growth. If we were unable to answer any of your questions, please reach out to our IR firm, MZ Group, We'll be more than happy to assist. With that, I wish everyone a good day.Read morePowered by